Acceptable, tolerable, manageable - but not to patients. How drug trials report harms.

episode

Medicine and Science from The BMJ not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Chris Hipkins: Labour Leader on their policy costings in the wake of PREFU, Adrian Rurawhe's death 10 min · 29 Sep 2026 · The Mike Hosking Breakfast

Nobody Knows What A Coincidence Is 36 min · 29 Sep 2026 · Toni and Ryan

NEW Nancy Guthrie Note?! Teresa Giudice Breaks Her Silence on Milania + Lindsay Clancy INNOCENT?! 52 min · 29 Sep 2026 · No Filter With Zack Peter

NPR News: 09-29-2026 2PM EDT 5 min · 29 Sep 2026 · NPR News Now

2PM ET 09/29/2026 Newscast 3 min · 29 Sep 2026 · Fox News Hourly Update

Deebo & Joe - Part 1: Reaction to Bears Beating Eagles + Maurkice Pouncey Joins 1h 4m · 29 Sep 2026 · Club Shay Shay

Report any issue

Source

Recorded19 Nov 2018

Publisherfeed.podbean.com ↗

Handlerec:13498300

Show notes

You’ll have read in a clinical trial “Most patients had an acceptable adverse-event profile.” Or that a drug “has a manageable and mostly reversible safety profile.” And that “the tolerability was good overall.” In this podcast, Bishal Gyawali (@oncology_bg) joins us to describe what events those terms were actually describing in cancer drug trials, and how they reduce the readers appreciation of the adverse effects of these novel drugs. Read the full analysis: https://www.bmj.com/content/363/bmj.k4383

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in